Azatadina


Azatadina Aviso médico
Nome IUPAC (sistemática)
11-(1-metilpiperidin-4-ildeno)-6,11-di-hidro-5H-benzo[5,6]ciclohepta[1,2-b]piridina
Identificadores
CAS	3964-81-6
ATC	R06AX09
PubChem	19861
DrugBank	DB00719
ChemSpider	18709
Informação química
Fórmula molecular	C₂₀H₂₂N₂
Massa molar	290.402 g/mol
SMILES	n4c3\C(=C1/CCN(C)CC1)c2ccccc2CCc3ccc
Farmacocinética
Biodisponibilidade	?
Metabolismo	?
Meia-vida	?
Excreção	?
Considerações terapêuticas
Administração	?
DL₅₀	?

Azatadina (nome comercial: Optimina) é um anti-histamínico de primeira geração e anticolinérgico que foi lançado pela Schering-Plough em 1973.^[1]^[2]

Foi patenteado em 1967.^[3] Tem sido sucedido por outros anti-histamínicos^[4] e as aprovações de marketing foram amplamente retiradas.^[5]^[6]^[7]^[8]^[9]

Ver também[editar | editar código-fonte]

Referências

↑ Katelaris, C. (1990). «Comparative effects of loratadine and azatadine in the treatment of seasonal allergic rhinitis». Asian Pacific Journal of Allergy and Immunology. 8 (2): 103–107. PMID 1982614
↑ Small, P.; Barrett, D.; Biskin, N. (1990). «Effects of azatadine, terfenadine, and astemizole on allergen-induced nasal provocation». Annals of Allergy. 64 (2 Pt 1): 129–131. PMID 1968324
↑ Azatadine, Villani, F. J.; Caldwell, W. Patente E.U.A. 3 326 924 (1967).
↑ Horak F. Antialergic and Vasoactive Drugs for Allergic Rhinitis. Chapter 4 in Allergy Frontiers:Therapy and Prevention. Volume 5 of Allergy Frontiers. Eds Pawankar R et al Springer Science & Business Media, 2010 ISBN 9784431993629
↑ Drugs.com Drugs.com listing for Azatadine Page accessed July 3, 2015
↑ Federal Register 2005 Food and Drug Administration Docket No.2005N-0058: Hospira, Inc. et al.; Withdrawal of Approval of 76 New Drug Applications and 60 Abbreviated New Drug Applications 70 FR 10651
↑ Federal Register 2007 Food and Drug Administration Docket No. 2004P-0262: Withdrawal of Approval of 128 Suitability Petitions 72 FR 8184
↑ Department of Economic and Social Affairs of the United Nations Secretariat Consolidated List of Products Whose Consumption and/or Sale Have Been Banned, Withdrawn, Severely Restricted or not Approved by Governments Twelfth Issue: Pharmaceuticals United Nations – New York, 2005
↑ FDA OGD Suitability Tracking Report (Sorted by Drug Name) Page accessed July 3, 2015

[1] Katelaris, C. (1990). «Comparative effects of loratadine and azatadine in the treatment of seasonal allergic rhinitis». Asian Pacific Journal of Allergy and Immunology. 8 (2): 103–107. PMID 1982614

[2] Small, P.; Barrett, D.; Biskin, N. (1990). «Effects of azatadine, terfenadine, and astemizole on allergen-induced nasal provocation». Annals of Allergy. 64 (2 Pt 1): 129–131. PMID 1968324

[3] Azatadine, Villani, F. J.; Caldwell, W. Patente E.U.A. 3 326 924 (1967).

[4] Horak F. Antialergic and Vasoactive Drugs for Allergic Rhinitis. Chapter 4 in Allergy Frontiers:Therapy and Prevention. Volume 5 of Allergy Frontiers. Eds Pawankar R et al Springer Science & Business Media, 2010 ISBN 9784431993629

[5] Drugs.com Drugs.com listing for Azatadine Page accessed July 3, 2015

[6] Federal Register 2005 Food and Drug Administration Docket No.2005N-0058: Hospira, Inc. et al.; Withdrawal of Approval of 76 New Drug Applications and 60 Abbreviated New Drug Applications 70 FR 10651

[7] Federal Register 2007 Food and Drug Administration Docket No. 2004P-0262: Withdrawal of Approval of 128 Suitability Petitions 72 FR 8184

[8] Department of Economic and Social Affairs of the United Nations Secretariat Consolidated List of Products Whose Consumption and/or Sale Have Been Banned, Withdrawn, Severely Restricted or not Approved by Governments Twelfth Issue: Pharmaceuticals United Nations – New York, 2005

[9] FDA OGD Suitability Tracking Report (Sorted by Drug Name) Page accessed July 3, 2015

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]